Long-term Immunogenicity and Boostability of the 13-valent Pneumococcal Conjugate Vaccine Followed by the 23-valent Pneumococcal Polysaccharide Vaccine in Adults Receiving Immunosuppressive Therapy and Adults With HIV—3-year Follow-up of a Prospective Cohort Study
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf438 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Jenny L Schnyder und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, Location Universit…. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, HIV Infections, Immunocompromised Host, Pneumococcal Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Netherlands Organisation for Health Research and Development.
Abstract (Originalsprache)
Background
The long-term immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) remains unclear among immunocompromised patients (ICPs).
Methods
This 3-year follow-up of a previously reported prospective cohort study included people with human immunodeficiency virus (HIV) (PWH), patients on immunosuppressive therapy, and immunocompetent controls who received PCV13 followed by PPSV23 2 months later. IgG levels for all 24 vaccine serotypes were measured 3 years after PCV13 (M36). The primary outcome was the seroprotection rate (SPR) at M36, defined as IgG concentrations ≥1.3 μg/mL for 17/24 vaccine serotypes. To assess immunological memory, we measured rapid recall responses 7 days after a PCV20 booster vaccination among initial responders 2 months after the priming schedule (M4) who had sero-reverted at M36.
Results
Between M4 to M36, SPRs dropped from 44% (22/50) to 9% (5/55) in PWH, from 55% (59/108) to 17% (22/131) in patients on immunosuppressive therapy and from 82% (14/17) to 42% (8/19) in controls. Rapid recall responses were observed in 40% (4/10) of PWH, 14% (2/14) of patients on immunosuppressive monotherapy, 22% (2/9) of patients on combination therapy, and 67% (2/3) of controls. Antibody levels increased significantly for 7/13 PCV20/PCV13-shared serotypes, but for none (0/7) of the PCV20/PPSV23-shared serotypes.
Conclusions
Only a minority of PWH and patients on immunosuppressive therapy and under half of controls remained seroprotected 3 years after vaccination. As rapid recall responses were limited to PCV serotypes, future research in ICPs should focus on expanded priming schedule with higher-valent PCVs such as PCV20.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
- Department of Experimental Immunology, Department of Haematology, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
- Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands.
ORCID-Profile: Jenny L Schnyder, Sabine Haggenburg, Hannah M Garcia Garrido, Martin P Grobusch, Abraham Goorhuis
Förderung
- The Netherlands Organisation for Health Research and Development
Zitieren
APA
Schnyder, J. L., Haggenburg, S., Garcia Garrido, H. M., Reiners, A., Meek, B., Grobusch, M. P., & Goorhuis, A. (2025). Long-term Immunogenicity and Boostability of the 13-valent Pneumococcal Conjugate Vaccine Followed by the 23-valent Pneumococcal Polysaccharide Vaccine in Adults Receiving Immunosuppressive Therapy and Adults With HIV—3-year Follow-up of a Prospective Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf438
Vancouver
Schnyder JL, Haggenburg S, Garcia Garrido HM, Reiners A, Meek B, Grobusch MP, et al. Long-term Immunogenicity and Boostability of the 13-valent Pneumococcal Conjugate Vaccine Followed by the 23-valent Pneumococcal Polysaccharide Vaccine in Adults Receiving Immunosuppressive Therapy and Adults With HIV—3-year Follow-up of a Prospective Cohort Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf438
BibTeX
@article{Schnyder2025,
author = {Schnyder, Jenny L and Haggenburg, Sabine and Garcia Garrido, Hannah M and Reiners, Anne and Meek, Bob and Grobusch, Martin P and Goorhuis, Abraham},
title = {Long-term Immunogenicity and Boostability of the 13-valent Pneumococcal Conjugate Vaccine Followed by the 23-valent Pneumococcal Polysaccharide Vaccine in Adults Receiving Immunosuppressive Therapy and Adults With HIV—3-year Follow-up of a Prospective Cohort Study},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf438}
}
EUVIMED